1. Home
  2. TYRA vs MCB Comparison

TYRA vs MCB Comparison

Compare TYRA & MCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • MCB
  • Stock Information
  • Founded
  • TYRA 2018
  • MCB 1999
  • Country
  • TYRA United States
  • MCB United States
  • Employees
  • TYRA N/A
  • MCB N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • MCB Major Banks
  • Sector
  • TYRA Health Care
  • MCB Finance
  • Exchange
  • TYRA Nasdaq
  • MCB Nasdaq
  • Market Cap
  • TYRA 844.2M
  • MCB 685.1M
  • IPO Year
  • TYRA 2021
  • MCB 2017
  • Fundamental
  • Price
  • TYRA $22.01
  • MCB $75.34
  • Analyst Decision
  • TYRA Strong Buy
  • MCB Buy
  • Analyst Count
  • TYRA 5
  • MCB 2
  • Target Price
  • TYRA $31.20
  • MCB $82.00
  • AVG Volume (30 Days)
  • TYRA 448.1K
  • MCB 98.9K
  • Earning Date
  • TYRA 11-05-2025
  • MCB 10-23-2025
  • Dividend Yield
  • TYRA N/A
  • MCB 0.80%
  • EPS Growth
  • TYRA N/A
  • MCB 8.50
  • EPS
  • TYRA N/A
  • MCB 5.80
  • Revenue
  • TYRA N/A
  • MCB $261,456,000.00
  • Revenue This Year
  • TYRA N/A
  • MCB $15.57
  • Revenue Next Year
  • TYRA N/A
  • MCB $13.99
  • P/E Ratio
  • TYRA N/A
  • MCB $12.96
  • Revenue Growth
  • TYRA N/A
  • MCB 1.27
  • 52 Week Low
  • TYRA $6.42
  • MCB $47.08
  • 52 Week High
  • TYRA $22.68
  • MCB $81.33
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 83.81
  • MCB 64.33
  • Support Level
  • TYRA $14.84
  • MCB $67.17
  • Resistance Level
  • TYRA $22.68
  • MCB $70.46
  • Average True Range (ATR)
  • TYRA 1.57
  • MCB 2.01
  • MACD
  • TYRA 0.71
  • MCB 1.04
  • Stochastic Oscillator
  • TYRA 94.18
  • MCB 91.40

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

Share on Social Networks: